Director Purchase

RNS Number : 0620D

Oxford Biomedica PLC

23 October 2020

 

Director Purchase

Oxford, UK - 23 October 2020:   Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Vulpes Life Sciences Fund ("Vulpes"), whose portfolio manager Martin Diggle is a Non-Executive Director on the Board of Oxford Biomedica, has purchased 25,000 ordinary shares of 50p each ("Ordinary Shares") in the Company on 22 October 2020 on the London Stock Exchange at a price of 779.6p per share. Following this purchase Vulpes Testudo/Vulpes Life Sciences Fund holds 10,738,616 ordinary shares representing 13.1% of the Company.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the transaction in number of Ordinary Shares.

1.	Details of the person discharging material responsibilities/person closely   associated
a.	Name	Vulpes Life Sciences Fund
2.	Reason for the notification
a.	Position/status	Martin Diggle, Non-Executive Director
b.	Initial notification /amendment	Initial notification
3.	Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford Biomedica plc
b.	Legal Entity Identifier	213800S1GVQNXQ15K851
4.	Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument identification code	Oxford Biomedica plc Ordinary Shares of 50p each  GB00BDFBVT43
b.	Nature of the transaction	Purchase of ordinary shares
c.	Currency	GBP - British Pound
d.	Price(s) and volume(s)	Price(s)	Volume(s)
		£7.80	25,000
e.	Aggregated information · Aggregated volume · Price · Aggregated total	25,000 £7.795807 £194,895.18
f.	Date of the transaction	2020-10-22
g.	Place of the transaction	London Stock exchange, Main List (XLON)

The issued share capital of the Group is 82,223,225 ordinary 50p shares.

-Ends-

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: [phone]

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a 3 year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 580 people. Further information is available at www.oxb.com

 

END

 

 

DSHZZMZGLFKGGZG